Sermonix Pharmaceuticals

Sermonix Pharmaceuticals is a clinical-stage biotech targeting a high-unmet need in women's oncology: advanced ER+/HER2- breast cancer that has developed ESR1 mutations after prior therapy. The company's sole clinical asset, lasofoxifene, is a selective estrogen receptor modulator (SERM) with unique tissue selectivity and is currently being evaluated in the pivotal Phase 2 ELAINE studies against the standard of care, fulvestrant. As a private company, Sermonix is positioned to advance this targeted therapy through clinical development, with the goal of providing a new oral treatment option for a genetically defined patient population that currently has limited effective therapies.

Exclusive rights to develop lasofoxifene, a novel selective estrogen receptor modulator (SERM) with unique tissue selectivity and potent antagonist activity against estrogen receptor alpha (ERα), particularly in the presence of ESR1 mutations.

Sermonix competes in the targeted ESR1-mutant breast cancer space against large pharmaceutical companies like AstraZeneca (camizestrant), Roche/Genentech (giredestrant), and Sanofi (amcenestrant). These rivals are developing oral Selective Estrogen Receptor Degraders (SERDs) and have greater resources for clinical development and future commercialization.